Magic Mushroom Compound Prevents Chemo Nerve Damage in Mice

Cancer patients facing chemotherapy may soon have hope for preventing one of treatment's most painful lasting side effects.

Researchers at the University of Texas MD Anderson Cancer Center discovered that psilocybin, the active compound in magic mushrooms, completely protected mice from chemotherapy-induced nerve damage across six treatment cycles. The findings, published Thursday in Science, mark the first time a psychedelic has been shown to prevent rather than just treat this kind of pain.

Peripheral neuropathy affects countless chemotherapy patients, causing tingling, numbness, and severe pain in hands and feet that can last years after treatment ends. Until now, doctors could only manage symptoms with ice packs and painkillers. There's been no way to stop it from happening.

The discovery happened almost by accident. When a researcher noticed mice given psilocybin didn't develop nerve damage after chemo, neuroscientist Moran Amit didn't believe it. He asked her to repeat the experiment.

"So she did, again and again and again," Amit said. The team tested it with tumors, without tumors, and with different chemotherapy drugs. Every time, the results held. "This is unparalleled," he said.

The key lies in how psilocybin protects the cellular "railroad system" that moves energy through nerve cells. Chemotherapy normally attacks microtubules, tiny structures that transport energy-producing mitochondria like trains on tracks. Psilocybin somehow keeps that railroad running despite the chemotherapy assault.

Why This Inspires

This research opens a completely new door for psychedelic medicine. While scientists have studied these compounds for treating depression, PTSD, and anxiety, this marks the first time they've shown real promise for preventing physical pain and protecting the body during medical treatment.

The team has already heard anecdotally from chemotherapy patients enrolled in psilocybin trials for other conditions who report improvement in nerve symptoms too. That real-world feedback strengthens their confidence the results will translate from mice to people.

Human trials begin in about a month with colorectal, breast, and head and neck cancer patients undergoing chemotherapy. For people facing treatment with no current option to prevent lasting nerve damage, Amit said the chance to participate offers genuine hope. "I think that it's definitely worth a shot."

A compound once dismissed as merely recreational may become a shield for cancer patients during their most vulnerable moments.